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Abstract
Background:  Estrogen/progestin replacement therapy (EPRT), alcohol consumption, physical
activity, and breast-feeding duration differ from other factors associated with breast cancer in being
immediately modifiable by the individual, thereby representing attractive targets for future breast
cancer prevention efforts. To justify such efforts, it is vital to quantify the potential population-level
impacts on breast cancer considering population variations in behavior prevalence, risk estimate,
and baseline incidence.
Methods: For each of these four factors, we calculated population attributable risk percents
(PARs) using population-based survey (2001) and cancer registry data (1998–2002) for 41
subpopulations of white, non-Hispanic California women aged 40–79 years, and ranges of relative
risk (RR) estimates from the literature.
Results: Using a single RR estimate, subpopulation PARs ranged from 2.5% to 5.6% for hormone
use, from 0.0% to 6.1% for recent consumption of >= 2 alcoholic drinks daily, and 4.6% to 11.0%
for physical inactivity. Using a range of RR estimates, PARs were 2–11% for EPRT use, 1–20% for
alcohol consumption and 2–15% for physical inactivity. Subpopulation data were unavailable for
breastfeeding, but PARs using published RR estimates ranged from 2% to 11% for lifetime
breastfeeding >= 31 months. Thus, of 13,019 breast cancers diagnosed annually in California, as
many as 1,432 attributable to EPRT use, 2,604 attributable to alcohol consumption, 1,953
attributable to physical inactivity, and 1,432 attributable to never breastfeeding might be avoidable.
Conclusion: The relatively feasible lifestyle changes of discontinuing EPRT use, reducing alcohol
consumption, increasing physical activity, and lengthening breastfeeding duration could lower
population breast cancer incidence substantially.
Background
Reducing the morbidity and mortality associated with
breast cancer, the most commonly diagnosed malignancy
in women, is a pressing public health concern. One part
of the response to the growing breast cancer burden is to
develop effective prevention strategies. Although many
breast cancer risk factors have been identified that might
form the basis of such strategies, prevention remains chal-
lenging, due in large part to practical difficulties in modi-
fying risk-increasing factors like nulliparity, late age at first
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full-term pregnancy, early age at menarche, and late age at
menopause[1,2]. However, some established risk factors
for breast cancer could be considered for practicable mod-
ification because they involve immediately modifiable
personal behaviors of adulthood. Examples include recent
use of estrogen/progestin -containing replacement ther-
apy (EPRT)[3], recent alcohol consumption[4], shorter
breastfeeding duration[5], and physical inactivity[6,7].
Implementing modifications in any of these behaviors
would require considerable efforts in health education
and policy. To justify such preventive strategies, it is
important first to quantify the theoretical impacts of
changes on breast cancer incidence at the population
level, but to date few analyses of this sort have occurred[8-
10]. A reasonable epidemiologic metric, the population
attributable risk (PAR), exists for estimating the effect on
disease rates of removing a risk factor from the popula-
tion. However, since the PAR takes into consideration
both disease incidence and risk factor prevalence, and
since these are well-established to vary across population
subgroups, a PAR determined for a single population has
limited utility for understanding the broader range of
impact that risk factor changes might have on breast can-
cer incidence.
Data from California, USA provide an as-yet unexplored
opportunity to circumvent this problem, since this state
has a large, demographically heterogeneous population
and routinely collects detailed breast cancer incidence and
risk factor data at the relatively small subpopulation level
of the county. In addition, California counties demon-
strate variation in both breast cancer incidence rates and
socioeconomic status generally representative of national
variation[11]. Therefore, we took advantage of California
county-level cancer registry and risk factor surveillance
data to estimate potential reductions in breast cancer inci-
dence for changes in four modifiable behaviors–usage of
EPRT, consumption of alcohol, physical inactivity and
sustained breastfeeding.
Methods
Analytic rationale
The PAR is calculated using the population prevalence of
the exposure (p) and the relative risk associated with the
exposure (r), as follows: PAR = p(r-1)/(1+p(r-1))[12]. We
obtained estimates of the prevalence and effect of the
exposures under consideration from population risk fac-
tor surveys and published epidemiological studies, as
described below. We then applied the PARs to breast can-
cer incidence rates for each of 41 California county-based
subpopulations defined by the California Health Inter-
view Survey (CHIS) to estimate the potential change in
case counts from reductions in exposure prevalence. We
limited our assessments to women of white, non-His-
panic race/ethnicity (hereafter referred to as white) in
order to minimize the influence of racial/ethnic distribu-
tions on differences among subpopulations, and because
the most reliable data on the risks of breast cancer associ-
ated with these exposures are from studies that included
mostly white women[3,4]. Furthermore, 2000 US Census
data show that Californian white women are generally
similar to white women nationally on most sociodemo-
graphic characteristics but with slightly higher levels of
education (21% vs.17% with bachelor's degree) and
annual household income ($53K vs. $45K)[13]. Lastly,
we restricted our analyses to women aged 40–79 years,
who are at highest risk of breast cancer.
We estimated PAR point estimates for two circumstances:
1) for each of the 41 California subpopulations while uti-
lizing a single value for the relative risk (RR), in order to
determine the range of likely PAR values across defined
subpopulations; and 2) for hypothetical populations with
varying exposure prevalences and varying degrees of risk
associated with those exposures, utilizing a range of likely
values for the RR and a realistic range of exposure preva-
lences based on the observed subpopulation distribu-
tions.
Breast cancer incidence and population data
Using data from the population-based California Cancer
Registry and population estimates from the California
Department of Finance, we calculated average annual
incidence rates of invasive breast cancer (ICD-O-3 site
codes 50.0–50.9) for the period 1998–2002 separately for
each of the 41 county groups. The software program
SEER*Stat. ([14] was used for all calculations.
Risk factor prevalence data
Risk factor prevalence ranges were estimated using data
collected by the CHIS program in 2001. The overall
response rate to the adult survey was 38%, reflecting both
the screener completion rate (i.e., success in surveying a
household to select a respondent) of 59%, and the
extended interview completion rate (i.e., success in inter-
viewing the selected respondent) of 64%[15]. We used the
internet-based AskCHIS[16], to obtain prevalences of
EPRT use, alcohol consumption, and physical inactivity
for each of the 41 county groups. To assess hormone ther-
apy (HT) use, CHIS asked women aged 40 and older who
were not pregnant: "Are you currently taking any hor-
mone replacement supplements prescribed by a medical
doctor to control the symptoms of menopause?" As this
question referred to any kind of HT, to estimate more
closely the population prevalence of women using EPRT
we excluded from the numerator of our prevalence calcu-
lations any women who reported both HT use and hyster-
ectomy (approximately half of all women reporting HT
use), because women with intact uteri are not prescribedBMC Cancer 2006, 6:170 http://www.biomedcentral.com/1471-2407/6/170
Page 3 of 11
(page number not for citation purposes)
estrogen-only HT because of demonstrated risks of
endometrial cancer[17].
To assess current alcohol consumption, CHIS asked all
adults: "During the past month, have you had at least one
drink of any alcoholic beverage such as beer, wine, wine
coolers, or liquor?"; those answering yes were also asked:
"During the past month, how many days per week or per
month did you drink any alcoholic beverages, on the aver-
age?" and "On the days when you drank, about how many
drinks did you drink on the average?" Answers to these
questions were used to calculate the prevalence of women
who reported drinking two or more alcoholic drinks per
day on 10 or more days in the last month.
To assess physical inactivity, CHIS asked all adults a series
of questions about their physical activity in the past 30
days, including whether respondents walked or bicycled
to work/errands. The CHIS variable "level of physical
activity" consolidated all of these questions into an indi-
cator with three levels: "no vigorous/moderate activity",
"some vigorous/moderate activity but doesn't walk/bicy-
cle", and "some vigorous/moderate activity and does
walk/bicycle". We used this variable to calculate the per-
centage of white women aged 40–79 years who reported
no vigorous/moderate activity in the last month.
Information regarding breastfeeding is not available from
CHIS. However, a recent review of population-based sur-
veys of breastfeeding prevalence[18], estimated that 60–
75% of parous white women initiated breastfeeding dur-
ing the period 1994–2001, suggesting that the prevalence
of not initiating breastfeeding ranged from 25% to 40%.
Estimates of relative risk
We obtained estimates of RRs for each risk factor as fol-
lows:
EPRT
The Women's Health Initiative (WHI), the only rand-
omized controlled trial of EPRT vs. placebo[3] found an
elevated risk of invasive breast cancer in participants after
a mean 5.2 years of follow-up, with a hazard ratio of 1.26
(95% confidence interval (CI) 1.00–1.59). A subsequent
meta-analysis (including this trial) concluded that RRs of
breast cancer among current users of estrogen/progestin
ranged from 1.2–1.4 and increased with duration of
use[19], compared to never users, although other studies
estimated the RR for current, long-term use to be as high
as 1.5[20,21]. Therefore, we used an RR of 1.26 for the
county-specific PAR calculations and a range of RRs from
1.2–1.4 to estimate PARs for hypothetical populations.
Alcohol consumption
A pooled analysis of 53 epidemiologic studies[4] identi-
fied RRs of breast cancer associated with consumption of
two or more alcoholic drinks per day (≥ 30 grams per day)
as compared to no drinks in the range of 1.3–1.4. A
pooled analysis of cohort studies[22] found that, com-
pared with non-drinkers, women consuming 30–60
grams of alcohol daily had a multivariate-adjusted RR of
1.41 (95% CI 1.18–1.69). For one of the California sub-
populations (Marin county), RRs associated with drinking
alcohol daily were 2.3 (95% CI 1.2–4.4) for 2 glasses and
3.6 (95% CI 1.2–11.5) for 3+ glasses[23]. Therefore, we
used an RR of 1.4 for the county-specific calculations and
a range of 1.4–2.2 for estimating PARs for hypothetical
populations.
Physical inactivity
A review of 36 epidemiologic studies identified RRs for
breast cancer associated with inactivity compared to mod-
erate physical activity in the range of 1.3–1.4 irrespective
of menopausal status[6]. This range was further supported
in a subsequent review by a National Cancer Institute
working group[7]. Therefore, we used an RR of 1.3 for the
county-specific calculations and a range of RRs from 1.2–
1.4 for estimating PARs for hypothetical populations.
Breastfeeding
A pooled analysis of 47 international breast cancer studies
(cohort, and hospital-based and population-based case-
control)[5] found that the RR for breastfeeding among
parous women decreased by 4.3% (95% CI 2.9%–5.8%)
for every 12 months beyond the influence of additional
births. With adjustment for parity and compared to
women who never breastfed, the RR of breast cancer was
0.88 (95% CI 0.82–0.94) for women who breastfed 31–
54 months and 0.73 (95% CI 0.63–0.83) for women who
breastfed for 55+ months over their lifetimes. For analyses
estimating PARs in hypothetical populations, we used RR
estimates in the range of 1.1–1.3 for not breastfeeding
compared with breastfeeding for at least 31 months.
Results
Subpopulation variation in breast cancer incidence
Overall, the average annual age-adjusted incidence rate of
invasive breast cancer among California white women
aged 40–79 years (331.6 per 100,000) was slightly higher
than the comparable national rate reported by SEER
(315.6 per 100,000). Table 1 presents breast cancer inci-
dence rates for each county-group subpopulation. Coun-
ties with the highest incidence rates (the urban areas of
Marin and San Francisco) had rates 45% higher than
counties with the lowest rates (the rural areas of Imperial
and Siskiyou/Lassen/Modoc/Trinity).BMC Cancer 2006, 6:170 http://www.biomedcentral.com/1471-2407/6/170
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EPRT
In 2001, prior to the release of WHI results, EPRT use var-
ied by over 100% among counties, ranging from 10.0% to
22.9% in a manner generally correlating with breast can-
cer incidence rate (Table 2). Using an RR estimate of
1.26[3], we found that the county-specific PAR estimates
for current EPRT use ranged from 2.5–5.6%, (Table 2).
Statewide, we estimated that approximately 4.5% of
breast cancer cases (567 cases) annually could be attrib-
uted to current use of EPRT. With a range of RR estimates
and population prevalences, PAR values for EPRT use
ranged from 2% (assuming EPRT utilization of 10% and
a relative risk of 1.2) to 11% (assuming EPRT utilization
of 30% and a relative risk of 1.4) (Figure 1).
Table 1: Average annual population counts, number of invasive breast cancer cases, and incidence rates in California Health Interview 
Survey-defined California county groups for non-Hispanic white women aged 40–79, 1998–2002.
California county group Population Cases Ratea
Siskiyou/Lassen/Modoc/Trinity 20,055 55 258.3
Imperial 6,795 21 273.5
Tulare 37,287 112 281.0
Tehama/Colusa/Glenn 17,096 53 284.8
Kern 72,647 215 285.1
Stanislaus 58,641 179 294.6
Mendocino/Lake 29,368 93 295.9
Madera 15,356 48 299.2
San Joaquin 62,562 195 300.0
Humboldt/Del Norte 28,529 88 304.6
San Luis Obispo 46,319 151 306.0
San Bernardino 163,317 512 307.1
Butte 38,390 131 309.7
Monterey/San Benito 46,548 151 309.8
Riverside 194,069 666 309.9
Merced 20,340 67 310.4
Tuolumne/Alpine/Amador/
Calaveras/Inyo/Mariposa/Mono
40,654 138 312.3
Shasta 34,222 115 318.1
Yolo 20,875 66 318.6
Santa Cruz 40,217 123 318.7
Sonoma 87,289 283 322.7
El Dorado 33,311 106 322.8
Fresno 76,816 262 323.2
Santa Barbara 54,635 190 324.2
Placer 49,738 165 328.2
Sutter/Yuba 19,714 68 329.6
Nevada/Plumas/Sierra 28,648 100 329.8
San Diego 349,009 1,193 330.0
Kings 10,115 35 333.5
Los Angeles 744,519 2,656 338.5
Solano 42,593 142 338.6
Orange 348,248 1,217 340.2
Ventura 98,544 344 348.3
Sacramento 161,327 581 349.8
Alameda 139,371 490 353.1
Santa Clara 177,331 643 354.9
Contra Costa 136,317 488 355.7
Napa 22,552 87 361.1
San Mateo 90,534 341 362.6
San Francisco 63,036 242 374.4
Marin 54,688 206 374.8
All California 3,781,621 13,019 331.6
SEER 80,072 315.6
a per 100,000/year and age-adjusted to the 2000 U.S. standard.B
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Table 2: Exposure prevalence and population attributable risk (PAR) for breast cancer among white non-Hispanic women ages 40–79 associated with current use of estrogen/progestin-
containing hormone therapy, consumption of 2+ alcoholic beverages/day, and physical inactivity in California Health Interview Survey-defined California county groups.
Estrogen/progestin hormone therapy Consumption of 2+ alcoholic beverages Physical inactivity
California county 
group
Exposure 
prevalence
PAR for RR 
= 1.26
Ratea if 
exposure 
removed
N cases 
due to 
exposure
Exposure 
prevalence
PAR for RR 
= 1.4
Ratea if 
exposure 
removed
N cases 
due to 
exposure
Exposure 
prevalence
PAR for RR = 
1.3
Ratea if 
exposure 
removed
N cases 
due to 
exposure
Siskiyou/Lassen/
Trinity/Modoc
10.00% 2.50% 251.8 1 5.00% 2.00% 253.2 1 30.8 8.50% 236.5 8
Imperial 16.70% 4.20% 262.1 1 0.00% 0.00% 273.5 0 34.1 9.30% 248.1 4
Tulare 19.40% 4.80% 267.5 5 5.60% 2.20% 274.9 2 33 9.00% 255.7 17
Tehama/Glenn/
Colusa
11.80% 3.00% 276.4 2 0.00% 0.00% 284.8 0 32.1 8.80% 259.8 9
Kern 11.40% 2.90% 276.9 6 8.60% 3.30% 275.7 7 30.7 8.40% 261.1 25
Stanislaus 13.00% 3.30% 285 6 7.30% 2.80% 286.3 5 34.6 9.40% 266.9 22
Mendocino, Lake 13.30% 3.40% 286 3 6.50% 2.50% 288.5 2 30.5 8.40% 271.1 13
Madera 13.30% 3.40% 289.2 2 0.00% 0.00% 299.2 0 24.8 6.90% 278.5 5
San Joaquin 12.10% 3.10% 290.8 6 4.60% 1.80% 294.6 3 29.4 8.10% 275.7 23
Humboldt/Del Norte 17.90% 4.40% 291.1 4 7.10% 2.80% 296.1 2 27.5 7.60% 281.4 8
San Luis Obispo 15.70% 3.90% 294 6 5.90% 2.30% 299 3 23.5 6.60% 285.8 19
San Bernadino 16.80% 4.20% 294.3 21 5.80% 2.30% 300.2 12 29.8 8.20% 281.9 52
Butte 12.50% 3.20% 300 4 7.50% 2.90% 300.7 4 26.9 7.50% 286.6 21
Monterey/San Benito 18.20% 4.50% 295.8 7 9.10% 3.50% 298.9 5 26.5 7.40% 287 17
Riverside 13.10% 3.30% 299.7 22 7.50% 2.90% 300.8 19 30.2 8.30% 284.2 115
Merced 16.70% 4.20% 297.5 3 0.00% 0.00% 310.4 0 36.7 9.90% 279.6 10
Tuolumne/Calaveras/
Amador/Inyo/
Mariposa/Mono/
Alpine
14.00% 3.50% 301.4 5 11.60% 4.40% 298.4 6 23.7 6.60% 291.6 19
Shasta 14.30% 3.60% 306.7 4 5.70% 2.20% 311 3 26.8 7.40% 294.4 14B
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Yolo 19.10% 4.70% 303.6 3 9.50% 3.70% 306.9 2 30.8 8.50% 291.7 5
Santa Cruz 21.10% 5.20% 302.2 6 12.80% 4.90% 303.2 6 19.4 5.50% 301.2 2
Sonoma 18.60% 4.60% 307.8 13 12.80% 4.90% 307 14 22.8 6.40% 302 19
El Dorado 13.20% 3.30% 312.1 3 12.80% 4.90% 307.1 5 20.7 5.80% 303.9 5
Fresno 16.90% 4.20% 309.6 11 6.50% 2.50% 315 7 28.7 7.90% 297.6 33
Santa Barbara 16.70% 4.20% 310.7 8 7.40% 2.90% 314.9 5 24.8 6.90% 301.7 25
Placer 13.20% 3.30% 317.3 5 9.40% 3.60% 316.3 6 20.5 5.80% 309.2 11
Sutter/Yuba 10.00% 2.50% 321.3 2 5.00% 2.00% 323.1 1 30.9 8.50% 301.6 9
Nevada/Plumas/Sierra 17.20% 4.30% 315.7 4 13.80% 5.20% 312.6 5 21.5 6.10% 309.8 11
San Diego 19.30% 4.80% 314.2 57 9.90% 3.80% 317.4 46 23.4 6.60% 308.4 117
Kings 11.10% 2.80% 324.1 1 0.00% 0.00% 333.5 0 41.2 11.00% 296.8 5
Los Angeles 18.10% 4.50% 323.3 119 7.90% 3.10% 328.2 81 30.5 8.40% 310.1 347
Solano 15.60% 3.90% 325.4 6 8.90% 3.40% 327 5 23.6 6.60% 316.2 7
Orange 19.30% 4.80% 324 58 9.20% 3.60% 328.1 43 27.7 7.70% 314.1 123
Ventura 17.00% 4.20% 333.6 15 5.00% 1.90% 341.5 7 26.2 7.30% 322.9 26
Sacramento 18.20% 4.50% 334 26 10.70% 4.10% 335.5 24 25.1 7.00% 325.3 56
Alameda 22.90% 5.60% 333.3 27 12.10% 4.60% 336.7 23 24.1 6.70% 329.3 31
Santa Clara 18.80% 4.70% 338.4 30 9.30% 3.60% 342.1 23 26.7 7.40% 328.6 60
Contra Costa 20.10% 5.00% 338 24 11.00% 4.20% 340.8 20 24.2 6.80% 331.6 36
Napa 22.70% 5.60% 341 5 9.10% 3.50% 348.4 3 24.1 6.70% 336.8 11
San Mateo 13.30% 3.40% 350.5 11 14.10% 5.40% 343.2 18 25 7.00% 337.3 36
San Francisco 20.30% 5.00% 355.7 12 13.50% 5.10% 355.2 12 22.2 6.20% 351 21
Marin 20.40% 5.00% 356 10 16.40% 6.10% 351.8 13 16.2 4.60% 357.4 11
All California 17.50% 4.40% 317.2 567 9.00% 3.50% 320.1 450 27.1 7.50% 306.7 1422
a per 100,000/year and age-adjusted to the 2000 U.S. standard
Table 2: Exposure prevalence and population attributable risk (PAR) for breast cancer among white non-Hispanic women ages 40–79 associated with current use of estrogen/progestin-
containing hormone therapy, consumption of 2+ alcoholic beverages/day, and physical inactivity in California Health Interview Survey-defined California county groups. (Continued)BMC Cancer 2006, 6:170 http://www.biomedcentral.com/1471-2407/6/170
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Alcohol consumption
Consumption of at least two alcoholic beverages per day
among white women aged 40–79 varied by over 100%
among counties, ranging from 0% to 16.4% also in a
manner generally correlating with breast cancer incidence
rate (Table 2). Prevalence was notably higher in northern
(Marin, Napa) than southern (Orange, Los Angeles)
urban counties. Using an RR estimate of 1.4[22], PAR esti-
mates for consumption of 2+ alcoholic drinks per day
ranged between 0.0% and 6.1% for county groups (Table
2). Overall in California, we estimated that about 3.5% of
breast cancer cases, or 450 per year were attributable to
this level of alcohol consumption. Considering ranges of
RR estimates from 1.4 to 2.2 and population prevalences
from 2% to 22%, we produced a corresponding range of
PAR values for alcohol consumption from 1% to 20%
(Figure 2).
Physical inactivity
White women aged 40–79 years reporting no vigorous/
moderate physical activity in the last month ranged from
16.1 to 41.0% by county (Table 2). Using an RR estimate
of 1.3[6], PAR estimates for physical inactivity ranged
between 0.0% and 6.1% for county groups (Table 2). We
estimated that statewide, 7.5% of breast cancer cases, or
1,422 cases per year, were attributable to a sedentary life-
style. Considering ranges of RR estimates from 1.2 to 1.4
and population prevalences from 15% to 45%, we esti-
mated a corresponding range of PARs of 2%–15% (Figure
3).
Breastfeeding
Using prevalences of never breastfeeding ranging from
25% to 40% and RRs ranging from 1.1 to 1.3, PAR esti-
mates for never breastfeeding (compared with breastfeed-
ing for at least 31 months over a lifetime) ranged from 2%
to 11% (Figure 4). According to CHIS, 16.4% of white
California women aged 40–79 years had never given
birth. Therefore, applying the PARs to the California pop-
ulation of parous white women aged 40–79 years, we esti-
mated that never breastfeeding (compared to
breastfeeding for 31+ months) could explain between 218
and 1,306 breast cancer cases yearly.
Discussion
This study quantified the theoretical reductions in breast
cancer to be expected from changes in EPRT use, alcohol
consumption, physical activity and breastfeeding dura-
tion for a range of socioeconomically heterogeneous pop-
ulations. Because the variation in breast cancer incidence
rates, risk factor prevalences, and socioeconomic status
across California is generally representative of national
variation[11], we believe that the range of PAR estimates
we obtained have relevance not only for 8 million white
Population attributable risk of breast cancer associated with  physical inactivity (reporting no moderate/vigorous activity in  past 30 days) for various levels of population prevalence and  relative risk Figure 3
Population attributable risk of breast cancer associated with 
physical inactivity (reporting no moderate/vigorous activity in 
past 30 days) for various levels of population prevalence and 
relative risk.
Population attributable risk of breast cancer associated with  use of combined estrogen/progestin replacement therapy  (EPRT) for various levels of exposure and relative risk Figure 1
Population attributable risk of breast cancer associated with 
use of combined estrogen/progestin replacement therapy 
(EPRT) for various levels of exposure and relative risk.
Population attributable risk of breast cancer associated with  consumption of 2 or more alcoholic drinks per day for vari- ous levels of population prevalence and relative risk Figure 2
Population attributable risk of breast cancer associated with 
consumption of 2 or more alcoholic drinks per day for vari-
ous levels of population prevalence and relative risk.BMC Cancer 2006, 6:170 http://www.biomedcentral.com/1471-2407/6/170
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California women, but also could reflect the range across
the US white population. Of 13,019 breast cancers diag-
nosed annually in Californian white women aged 40–79
years, our data suggest that as many as 1,432 (11%) may
be attributable to EPRT use, 2,604 (20%) may be attribut-
able to consuming 2 or more alcoholic drinks daily, 1,953
(15%) may be attributable to physical inactivity and
1,432 (11%) may be attributable to never breastfeeding.
Our data suggest that the proportions of women consum-
ing two or more alcoholic drinks daily may have a greater
influence on breast cancer incidence than previously esti-
mated, particularly in high-incidence subpopulations. A
pooled analysis of 53 studies estimated that 4% of breast
cancer cases in developed countries were attributable to
alcohol, based on average consumption of 6.0 g/day in
controls[4]. Data from the Third National Health and
Nutrition Examination Survey, reporting prevalences of
light (0.1–6.4 g/day), moderate (6.5–25.9 g/day) and
heavy (26+ g/day) drinking of 27%, 13% and 3% respec-
tively, were used to produce a PAR of 2.1% across all lev-
els[10]. Our estimates of possible PARs for consuming
two or more drinks daily included a range with much
higher values (1% to 20%). At the low end of our RR
range, PAR estimates exceeded 5% for Marin and San
Francisco counties, which have among the highest breast
cancer rates among all counties in California and in the
non-California regions of the SEER program[24]. If preva-
lence of alcohol consumption now is higher than in pre-
viously examined populations; a public health effort
aimed at reducing alcohol consumption below two drinks
daily may be an increasingly important strategy for breast
cancer prevention in particular subpopulations of white
women. A more specific recommendation needs to con-
sider the balance of health risks and benefits for alcohol
consumption, which may protect against ischemic heart
disease and myocardial infarction[25], diseases with
greater mortality risks than breast cancer. An alternative
strategy to reducing alcohol intake[26] may be for women
to increase folate intake through supplementation or food
supply fortification, as recent evidence from the Nurses
Health Study showed no adverse influence of alcohol on
breast cancer occurrence among women with high plasma
folate[27].
Although the presumed effect of physical activity on
breast cancer risk is not large (RR = 1.3–1.4), the highly
prevalent nature of physical inactivity corresponded to a
California-wide PAR of 7.5%. Especially at the high end of
our estimated PAR range (15%), the potential for physical
activity interventions to reduce breast cancer incidence
may be underestimated. The CHIS statewide average of
27% of women reporting inactivity is higher than that
reported in previous PAR estimation efforts[28] and
underscores the importance of ongoing public health
efforts to increase physical activity for its well-known,
wide range of health benefits.
We found that use of EPRT at the levels occurring in 2001
may have explained 2.5% to 5.6% of breast cancer in
white California women, but could have been responsible
for as much as 11%, depending on the associated RR.
Coombs et al. recently used CHIS data to estimate that HT
(irrespective of formulation) was attributable for 4.3–
17.4% of breast cancer in California in 2001, depending
on the RR[9]. Findings from the Women's Health Initia-
tive (WHI) on risks of long-term EPRT use, released in
2002 after the collection of the data used in this analysis,
appear to have had a dramatic effect on EPRT prescribing
and usage patterns, with declines of up to 50% reported in
some cohorts. Thus, long-term use is now much less likely
to be recommended by physicians to reduce risks of oste-
oporosis and cardiovascular disease[29], although some
women continue to use EPRT for treatment of menopau-
sal symptoms. Our results would predict that reductions
in EPRT use related to the WHI results could result in
breast cancer incidence rate declines between 5% and
15%, depending on population characteristics.
Our findings also indicate that the number of breast can-
cer cases occurring in California might be reduced by as
much as 11% by encouraging breastfeeding for 31 months
or more (a time period derived from a meta-analysis that
could be refined in further analyses). Lengthening the
duration of breastfeeding among childbearing women
depends in part on individual circumstances, including
parity and medical conditions interfering with breastfeed-
ing, as well as on societal influences beyond individual
control (e.g., cultural support of breastfeeding, workplace
Population attributable risk of breast cancer associated with  not breast feeding (compared to breastfeeding for 31 months  or more over a lifetime) for various levels of population  prevalence and relative risk Figure 4
Population attributable risk of breast cancer associated with 
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policies for maternal leave and breast pumping). Never-
theless, our data support continued public policy efforts
to encourage longer duration of breastfeeding in child-
bearing women, which for a woman bearing two children
equates to breastfeeding each child slightly more than one
year, particularly given the overwhelming evidence of
breastfeeding benefit to the infant.
The PAR has had many previous applications to breast
cancer, predominantly to estimate the percentage of cases
"explained" by established risk factors using results from
a single study[10,28,30,31]. Madigan et al. estimated that
well-established risk factors for breast cancer (later age at
first birth, nulliparity, higher income, and family history
of breast cancer) together accounted for 41% of U.S.
breast cancer cases[30]. Mezzetti et al. estimated that the
attributable risk in an Italian population was 10.7% for
high alcohol consumption, 15.0% for low beta-carotene
intake, and 11.6% for low physical activity, with the three
factors together accounting for 33% of breast cancer
cases[28]. Rockhill et al. estimated that 25% (95% CI 6%
– 48%) of breast cancer cases could be attributed to
menarche before age 14 years, nulliparity/first birth after
age 20 years, family history, and history of benign breast
biopsy[31]. However, these studies did not aim to quan-
tify potential case count reductions from changes in risk
factor prevalence, as we have done.
Our study has several limitations. Our statistic of choice,
the PAR, is a useful measure for quantifying the extent of
disease reduction possible through behavior modifica-
tion, but its interpretation can be complex, particularly as
it relates to the interrelationships of factors of interest
with other established risk factors and changes in popula-
tion prevalence. In addition, the PAR does not incorporate
processes of risk latency and reversibility for exposures;
for example, breast cancer risk increases with duration of
EPRT use and declines after EPRT cessation[21], effects we
could not capture. The PAR also is sensitive to the refer-
ence (i.e., minimum risk) category chosen. To minimize
the effect of these limitations, we restricted our analysis to
a relatively homogeneous group, white women aged 40–
79 years, and used systematically collected estimates of
exposure prevalence in categories for which multiple RR
estimates were available. Exposure prevalence estimates,
although based on the best available population data, are
subject to sampling variation, response and misclassifica-
tion bias. The AskCHIS program uses a weighting proce-
dure to compensate for differential selection probabilities
for households and persons, which attempts to minimize
selection bias and adjusts, to the extent possible, for
undercoverage in the sampling frames[15]. Although RR
estimates were taken from pooled analyses or other multi-
study efforts, they remain subject to bias or uncontrolled
confounding. To help account for this problem, we exam-
ined a range of possible RR values. Empirically derived
ranges of values for RR and exposure prevalence may be
more difficult to interpret but are more useful for future
public health consideration. Lastly, our PAR estimates
cannot be summed together to produce a combined PAR
estimate for removing all three risk factors from the pop-
ulation, because these factors are likely to be correlated;
moreover, we did not calculate multivariate PARs because
RRs for the combinations of all three risk factors were not
available.
We restricted our analysis to white non-Hispanic women
because few studies have included sufficient numbers of
women from non-white racial/ethnic groups to obtain
reliable RR estimates for the exposures we considered
here[32]. Based on the limited data available[32,33], it is
likely that incidence reduction in nonwhite groups also
may be anticipated from changes in these behaviors.
Statewide CHIS data suggested that the prevalences of
combined EPRT use and consumption of at least two alco-
holic drinks per day were considerably lower in African
American, Asian and Hispanic women in 2001 than in
white women, at 7%, 13% and 9%; and 2.7%, 0.8% and
0.9%, respectively. Average annual age-adjusted incidence
rates of breast cancer were also much lower in these ethnic
groups, at 263, 194 and 197 per 100,000 women per year
for the period 1998–2002 in California. Thus, for these
factors, PARs for non-white women may be considerably
lower than those we estimated in white women. On the
other hand, prevalence of physical inactivity was notably
higher in African American, Asian and Hispanic women
(45%, 45%, 57%, respectively), such that PARs and pre-
sumable breast cancer preventive benefits could be higher
for remediating physical inactivity in non-white
women[33] than our estimates for white women.
Conclusion
Our results suggest that public health interventions to fur-
ther reduce the proportions of women taking EPRT, drink-
ing two or more alcoholic beverages daily, being
physically inactive or not breastfeeding could substan-
tially decrease the numbers of new breast cancer cases
and, furthermore, may have a greater impact on breast
cancer risks than previously estimated by others[4,10],
particularly in high incidence populations where these
risk factors tend to be more prevalent. Given the relative
feasibility of implementing these changes and the other
health benefits already associated with them, public
health efforts toward this end are warranted.
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